Genomic Correlations for Clinical Outcomes in HER2-positive Advanced Gastric Cancer Treated Using Trastuzumab-based Therapy
<i>ERBB2</i> focal amplification is associated with improved outcomes in trastuzumab-treated patients with HER2-positive gastric cancer, whereas <i>NOTCH3</i> alterations predict a poor prognosis. These genomic features may support risk stratification and therapeutic decisions.
Authors
- H. Lee
- JAEWON HYUNG
- Hyung‐Don Kim (ORCID: https://orcid.org/0000-0001-9959-0642)
- Sun‐Young Lee (ORCID: https://orcid.org/0000-0003-4146-6686)
- Min-Hee Ryu
- Young Soo Park
- Meesun Moon
Institutions
- Ulsan College (KR)
- Asan Medical Center (KR)
- University of Ulsan (KR)
Publication Details
- Journal
- Anticancer Research
- Published
- 2025-11-29
- DOI
- https://doi.org/10.21873/anticanres.17901
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00